Neurosense Therapeutics Ltd
Change company Symbol lookup
Select an option...
NRSN Neurosense Therapeutics Ltd
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
XNXNX Nuveen New York Select Tax Free Income Portfolio
DHHC DiamondHead Holdings Corp
WFC Wells Fargo & Co
Go

Health Care : Biotechnology |
Based in Israel
Company profile

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Postmarket

Last Trade
Delayed
$1.62
-0.026 (-1.58%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.65
Day's Change
0.016 (0.98%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.66
Day's Low
1.60
Volume
(Average)
Volume:
13,585

10-day average volume:
12,984
13,585

Display:

Providers:

UpdateCancel
6 providers
December 01, 2022
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update. (PR Newswire)

November 16, 2022
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in...(PR Newswire)

November 15, 2022
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

-- NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy -- Follows a successful U.S. pharmacokinetic (PK) study which confirmed PrimeC's favorable extended release...(PR Newswire)

October 27, 2022
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming...(PR Newswire)

October 21, 2022
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe(R) Partnering Conference on October 24-26, 2022 in Lepzing...(PR Newswire)

October 18, 2022
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of...(PR Newswire)

October 12, 2022
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City

Investors and analysts interested in participating in the Summit via webinar may register here: LINK NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced...(PR Newswire)

September 29, 2022
NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative...(PR Newswire)

September 21, 2022
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

-- Biomarker data to be presented provide indication of PrimeC's efficacy in ALS -- Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks -- Topline results expected H1 2023 (PR Newswire)

September 20, 2022
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial

-- PrimeC is safe and tolerable at over 4x the maximal clinical dose -- Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...(PR Newswire)

September 19, 2022
NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

-- Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks -- PrimeC showed a statistically significant impact on key disease-related...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.